ProShares UltraShort NASDAQ Biotechnology
4 hedge funds and large institutions have $542K invested in ProShares UltraShort NASDAQ Biotechnology in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
2.31% more ownership
Funds ownership: 9.8% → 12.11% (+2.3%)
14% less capital invested
Capital invested by funds: $629K → $542K (-$86.5K)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
+$185K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$112K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.22K |
| 3 |
Morgan Stanley
New York
|
-$47 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $313K | -$112K | -3,762 | -24% |
|
|
CAG
2
Csenge Advisory Group
Clearwater,
Florida
| $163K | +$185K | +6,211 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $66.5K | +$18.8K | +631 | +33% |
|
|
4
UBS Group
Zurich,
Switzerland
| $13 | -$3.22K | -108 | -99% |
|
|
5
Morgan Stanley
New York
| – | -$47 | -1 | Closed |
|
BIS Hedge Fund Activity: Q3 2025 in Review
4 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2025, worth a combined $542K — down 14% from $629K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Csenge Advisory Group, opening a new position worth an estimated $185K. The largest seller was Susquehanna International Group, cutting an estimated $112K.
- 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2025, down from 5 in Q2 2025.
- Funds reported $542K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2025, down 14% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2025 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2025 was Csenge Advisory Group, an estimated $185K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2025 was Susquehanna International Group, an estimated $112K sold.
Based on aggregated 13F filings for Q3 2025.